Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06389123 · ClinicalTrials.gov registry record · Phase 1
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
A Phase 1 study of Metastatic Cancer, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06389123: Recruiting Phase 1 study of Metastatic Cancer, sponsored by University of California, Davis.
NCT06389123 is a Phase 1 study of Metastatic Cancer that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 40 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06389123, a Phase 1 study of Metastatic Cancer, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
Primary Outcome
To assess the ability of \[68Ga\]Ga DOTA-5G to detect lesions in patients with metastatic cancer
Conditions Studied
Interventions
- DRUG [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Study Locations (1)
California
- The University of California Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 1 |
What NCT06389123 shows while recruiting
NCT06389123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. is the first listed.
NCT06389123 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06389123 about?
NCT06389123 is a clinical study titled "Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas". This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
What is the current status of trial NCT06389123?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-04-01. Estimated completion is 2028-03-31.
What conditions does trial NCT06389123 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT06389123?
The interventions under investigation include: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. (DRUG).
Who is sponsoring clinical trial NCT06389123?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06389123 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06389123's enrollment target sits among peer trials
40 67th of 109 higher than 38 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI